Fachpublikationen:
Zum Thema Darmkrebs:
Identification of BCL-XL as highly active survival factor and promising therapeutic target in colorectal cancer. Scherr A-L, Schulze-Bergkamen H, Köhler BC, Cell Death Dis. 2020 Oct 17;11(10):875
Knockdown of Atg7 Induces Nuclear-LC3 Dependent Apoptosis and Augments Chemotherapy in Colorectal Cancer Cells. Scherr A-L 1, Jassowicz A 1, Pató A, Elssner C, Ismail L, Schmitt N, Hoffmeister P, Neukirch L, Gdynia G, Goeppert B, Schulze-Bergkamen H, Jäger D, Köhler BC, Int J Mol Sci. 2020 Feb 7;21(3):1099.
Zum Thema Grundlagenforschung:
MCL1 Is Required for Maintenance of Intestinal Homeostasis and Prevention of Carcinogenesis in Mice.Healy ME, Schulze-Bergkamen H, Weber A, Gastroenterology 2020 Jul;159(1):183-199
Zum Thema Speiseröhrenkrebs:
A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study. Türeci O, Sahin U, Schulze-Bergkamen H, Clinical Trial, Ann Oncol. 2019 Sep 1;30(9):1487-1495
Zum Thema Lungenkrebs:
A randomized, multicenter phase II study comparing efficacy, safety and tolerability of two dosing regimens of cisplatin and pemetrexed in patients with advanced or metastatic non-small-cell lung cancer. Metzenmacher M, Hoiczyk M, Eberhardt WEE, Ther Adv Med Oncol. 2021 Mar 9;13:1758835921996506.
Zum Thema Leberzellkrebs:
Survival of Hepatocellular Carcinoma Patients Treated with Sorafenib beyond Progression. Apostolidis L, Pfeiffenberger J, Gotthardt D, Radeleff B, Mehrabi A, Schemmer P, Jäger D, Schirmacher P, Stremmel W, Schulze-Bergkamen H, Springfeld C, Weiss KH. Gastrointest Tumors. 2018 Sep;5(1-2):38-46
Zum Thema Gallenwegskrebs:
An undifferentiated carcinoma at Klatskin-position with long-term complete remission after chemotherapy. Köhler BC, Goeppert B, Waldburger N, Schlamp K, Sauer P, Jäger D, Weiss KH, Macher-Göppinger S, Schulze-Bergkamen H, Schirmacher P, Springfeld C., Oncotarget. 2018 Apr 24;9(31):22230-22235.
Zum Thema innovative neue Krebsmedikamente:
Phase I study of tomuzotuximab, a glycoengineered therapeutic antibody against the epidermal growth factor receptor, in patients with advanced carcinomas.
Fiedler W, Cresta S, Schulze-Bergkamen H, De Dosso S, Weidmann J, Tessari A, Baumeister H, Danielczyk A, Dietrich B, Goletz S, Zurlo A, Salzberg M, Sessa C, Gianni L, ESMO Open. 2018 Feb 1;3(2):e000303.
Neueste Publikation der Arbeitsgruppe Prof. Schulze-Bergkamen mit dem NCT Heidelberg (in der international führenden Fachzeitschrift für Magen-Darm-Erkrankungen):
Nuclear Translocation of RELB is Increased in Diseased Human Liver and Promotes Ductular Reaction and Biliary Fibrosis in Mice.Elßner C, Goeppert B, Longerich T, Scherr AL, Stindt J, Nanduri LK, Rupp C, Kather JN, Schmitt N, Kautz N, Breuhahn K, Ismail L, Heide D, Hetzer J, García-Beccaria M, Hövelmeyer N, Waisman A, Urbanik T, Mueller S, Gdynia G, Banales JM, Roessler S, Schirmacher P, Jäger D, Schölch S, Keitel V, Heikenwalder M, Schulze-Bergkamen H, Köhler BC., Gastroenterology. 2018 Nov 13. pii: S0016-5085(18)35260-0